Text Version |Site map | Contact Us | Temple University | FAQs | Search
Prospective Students | Current Students | Faculty/Preceptors | Alumni

Why Temple School of Pharmacy

cGMP Services
cGMP Services
Moulder Center

Faculty & Staff Directory


Jon H. Condra, Ph.D

Associate Professor

Pharmaceutical Biotechnology

Department of Pharmaceutical Sciences

and Moulder Center for Drug Discovery Research


3307 N. Broad Street

Philadelphia, PA 19140

office Room 501

phone (215) 707-1642

email jon.condra@temple.edu

Biosketch | Selected Publications


1. Condra, J.H., W.A. Schleif, O.M. Blahy, L.J. Gabryelski, D.J. Graham, J.C. Quintero, A. Rhodes, H.L. Robbins, E. Roth, M. Shivaprakash, D. Titus, T. Yang, H. Teppler, K.E. Squires, P.J. Deutsch and E.A. Emini (1995). In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571.

2. Condra, J.H., D.J. Holder, W.A. Schleif, O.M. Blahy, R.M. Danovich, L.J. Gabryelski, D.J. Graham, D. Laird, J.C. Quintero, A. Rhodes, H.L. Robbins, E. Roth, M. Shivaprakash, T. Yang, J.A. Chodakewitz, P.J. Deutsch, R.Y Leavitt, F.E. Massari, J.W. Mellors, K.E. Squires, R.T. Steigbigel, H. Teppler and E.A. Emini (1996). Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. Journal of Virology 70:8270-8276.

3. Condra, J.H. and E.A. Emini (1997). Preventing HIV-1 drug resistance. Science & Medicine 4(1):14-23.

4. Gulick, R.M., J.W. Mellors, D. Havlir, J.J. Eron, C. Gonzalez, D. McMahon, D.D. Richman, F.T. Valentine, L. Jonas, A. Meibohm, E.A. Emini, P. Deutsch, D. Holder, W.A. Schleif, J.H. Condra and J.A. Chodakewitz (1997). Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New England Journal of Medicine 337:734-739.

5. Condra, J.H. (1998). Resisting resistance: maximizing the durability of antiretroviral therapy. Annals of Internal Medicine 128:951-954.

6. Emini E.A. and J.H. Condra. Protease inhibitors. In: Merigan T.C., Bartlett J.G., Bolognesi D., ed. The Textbook of AIDS Medicine, Second ed. Baltimore, MD: Williams & Wilkins, 1998, pp. 848-859.

7. Gulick, R.M., J.W. Mellors, D. Havlir, J.J. Eron, C. Gonzalez, D. McMahon, L. Jonas, A. Meibohm, D. Holder, W.A. Schleif, J.H. Condra, E.A. Emini, R. Isaacs, J.A. Chodakewitz and D.D. Richman (1998). Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine and lamivudine for HIV-1 infection: 100-week follow-up. Journal of the American Medical Association.280:35-41.

8. Gulick, R.M., J.W. Mellors, D. Havlir, J.J. Eron, A. Meibohm, J.H. Condra, F.T. Valentine, D. McMahon, C. Gonzalez, L. Jonas, E.A. Emini, J.A. Chodakewitz, R. Isaacs and D.D. Richman (2000). 3-year suppression of HIV viremia with indinavir, zidovudine and lamivudine. Annals of Internal Medicine 133(1):35-39.

9. Para, M.F., D.V. Glidden, R.W. Coombs, A.C. Collier, J.H. Condra, C. Craig, R. Bassett, R. Leavitt, S. Snyder, V. McAuliffe and C. Boucher, for the AIDS Clinical Trials Group Protocol 333 Team (2000). Baseline human immunodeficiency virus type 1 phenotype, genotype and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333. Journal of Infectious Diseases 182(3):733-743.

10. Condra, J.H., C.J. Petropoulos, R. Ziermann, W.A. Schleif, M. Shivaprakash and E.A. Emini (2000). Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy. Journal of Infectious Diseases 182(3):758-765.

11. Condra, J.H. and J.P. Vacca (2002). HIV-1 protease inhibitors. In: Emini, E.A., ed. The Human Immunodeficiency Virus: Biology, Immunology and Therapy, Princeton, NJ: Princeton University Press: pp. 172-222.

12. Condra, J.H., M.D. Miller, D.J. Hazuda and E.A. Emini (2002). Potential new therapies for the treatment of HIV-1 infection. Annual Review of Medicine 53:541-555.

13. Saah, A.J., D.W. Haas, M.J. Nubile, J. Chen, D.J. Holder, R.R. Rhodes, M. Shivaprakash, K.K. Bakshi, R.M. Danovich, D.J. Graham and J.H. Condra (2003). Treatment with indinavir, efavirenz and adefovir after failure of nelfinavir therapy. Journal of Infectious Diseases 187 (1 April):1157-62.

14. Campo, R.E., J.N. Moreno, G. Suarez, N. Miller, M.A. Kolber, D.J. Holder, M. Shivaprakash, D.M. DeAngelis, J.L. Wright, W.A. Schleif, E.A. Emini and J.H. Condra (2003). Efficacy of indinavir/ritonavir-based regimens in HIV-1-infected patients with prior protease inhibitor failures. AIDS 17:1933-1939.

15. Finnefrock, A.C., X. Liu, D.W. Opalka, J.W. Shiver, D.R. Casimiro and J.H. Condra (2007). HIV-1 vaccines for worldwide use: predicting in-clade and cross-clade breadth of immune responses. AIDS Research and Human Retroviruses 23(10):1283-1292.

16. Montgomery, D.L., Y.-J. Wang, R. Hrin, M. Luftig, B. Su, M.D. Miller, F. Wang, P. Hatyko, L. Huang, S. Vitelli, J. Condra, X. Liu, R. Hampton, A. Carfi, A. Pessi, E. Bianchi, J. Joyce, C. Lloyd, R. Geleziunas, D. Bramhill, V.M. King, A. Finnefrock, W. Strohl and Z. An (2009). Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41. mAbs 1(5): 1-12.

17. Ni, Y.G., J.H. Condra, L. Orsatti, X. Shen, S. DiMarco, S. Pandit, M.J. Bottomley, L. Ruggeri, R.T. Cummings, R.M. Cubbon, J.C. Santoro, A. Ehrhardt, D. Lewis, T.S. Fisher, S. Ha, L. Njimoluh, D.D. Wood, H.A. Hammond, D. Wisniewski, C. Volpari, A. Noto, P. Lo Surdo, B. Hubbard, A. Carfi and A. Sitlani (2010). A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen binding fragment inhibits PCSK9 internalization and restores LDL-uptake. Journal of Biological Chemistry 285:12882-12891.

18. Ni,Y.G., S. Di Marco, J.H. Condra, L.B. Peterson, W. Wang, F. Wang, S. Pandit, H.A. Hammond, R. Rosa, R.T. Cummings, D.D. Wood, X. Liu, M.J. Bottomley, X. Shen, R.M. Cubbon, S-P. Wang, D. Johns, C. Volpari, , L. Hamuro, J. Chin, L. Huang, J.Z. Zhao, S. Vitelli, P. Haytko, D. Wisniewski, L.J. Mitnaul, C.P. Sparrow, B. Hubbard, A. CarfĂ­ and A. Sitlani (2011). A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo. Journal of Lipid Research 52(1):78-86.

19. Zhang, L., T. McCabe, J.H. Condra, Y.G. Ni, L.B. Peterson, W. Wang, A.M. Strack, F. Wang, S. Pandit, H. Hammond, D. Wood, D. Lewis, R. Rosa, V. Mendoza, A.M Cumiskey, D.G. Johns, B.C. Hansen, X. Shen, N. Geoghagen, K. Jensen, L. Zhu, K. Wietecha, D. Wisniewski, L. Huang, J.Z. Zhao, R. Ernst, R. Hampton, P. Haytko, F. Ansbro, S. Chilewski, J. Chin, L.J. Mitnaul, A. Pellacani, C.P. Sparrow, Z. An, W.R. Strohl, B. Hubbard, A.S. Plump, D. Blom, and A. Sitlani(2012). An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes. International Journal of Biological Sciences 8(3): 310-327.